Combining Lenvatinib with SIRT for Advanced Liver Cancer
Official title: Lenvatinib Combined With Yttrium-90 Selective Internal Radiation Therapy (SIRT) Versus Lenvatinib Alone in TACE-Refractory Hepatocellular Carcinoma: A Prospective Non-Randomized Controlled Study
Run by Second Affiliated Hospital of Guangzhou Medical University · NCT06904196 · Data updated 2026-11-12
This study is testing whether combining a cancer drug called lenvatinib with a type of radiation therapy can help people with advanced liver cancer that hasn't improved with other treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 78 (estimated) |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy, lenvatinib |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | March 31, 2028 |
| Study ends | March 31, 2029 |
| Registry record updated | April 29, 2025 |
| Trial ID | NCT06904196 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with pathologically confirmed HCC who have not responded to TACE and have measurable intrahepatic lesions.
✕Probably not a fit
Patients with extrahepatic metastasis or those with severe liver dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness and safety of combining lenvatinib with selective internal radiation therapy (SIRT) compared to lenvatinib alone in patients with hepatocellular carcinoma (HCC) that has not responded to transarterial chemoembolization (TACE). The study will enroll 78 patients, who will be assigned to either the combination treatment or lenvatinib alone. The primary goal is to measure the objective response rate, while secondary goals include assessing disease control rate, progression-free survival, and overall survival. Treatment will continue until disease progression or other specified criteria are met.
Why it matters
Potential benefit: If successful, this approach could provide a more effective treatment option for patients with TACE-refractory HCC.
How similar studies have gone: While this approach is innovative, similar studies combining targeted therapies with radiation have shown promise in other cancer types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed or clinically diagnosed HCC * Diagnosis of HCC with TACE refractoriness according to the criteria proposed by Japan Society of Hepatology (2021) * Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included * At least one measurable intrahepatic target lesion * Child-Pugh class A/B * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Tumor extent \<70% liver occupation * Candidates for SIRT must be confirmed suitable for SIRT after evaluation (including SPECT/CT evaluation after arterial perfusion with 99Tc-MAA) * Adequate organ and hematologic function with platelet count ≥50×10\^9/L, leukocyte \>3.0×10\^9/L, Neutrophil count ≥1.5×10\^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds * Life expectancy of at least 3 months Exclusion Criteria: * Extrahepatic metastasis * Tumor thrombus involving main portal vein or both the first left and right branches of portal vein * Vena cava invasion * Patients who received prior hepatic arterial infusion chemotherapy (HAIC), radiotherapy, or systemic therapy, for HCC * History of organ and cell transplantation * History of esophageal or gastric variceal bleeding * History of hepatic encephalopathy * History of other malignancies * Human immunodeficiency virus infection
Where it's running
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Mingyue Cai, Dr.
- Email: cai020@yeah.net
- Phone: +86-20-34156205
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combination treatment for large liver cancer with portal vein involvement
This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.
-
Triple therapy for patients with unresectable liver cancer
This study is testing a new combination treatment for patients with hard-to-treat liver cancer to see if it can help shrink tumors more and improve survival rates.
-
Combining lenvatinib with TACE and HAIC for large liver cancer with portal vein thrombosis
This study is testing a new combination treatment for people with large liver cancer and blood clots in the portal vein to see if it works better than just one of the treatments alone.
-
Combination therapy for advanced liver cancer
This study is testing a new combination of treatments for advanced liver cancer to see if it can shrink tumors enough to make them operable.
-
Comparing two treatment combinations for advanced liver cancer
This study is testing two different treatment combinations for advanced liver cancer to see which one helps patients live longer after their first round of a specific procedure.
-
Combining lenvatinib with iodine-125 seed brachytherapy for treating liver cancer
This study is testing if combining a medication called lenvatinib with a special type of radiation therapy can help people with liver cancer that hasn't improved with other treatments live longer and feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.